Partnering for impact: why HDRS and The BARBARA Alliance are joining forces to accelerate dementia research
By Dr Melanie Ivarsson, CEO of Health Data Research Service (HDRS), and Jessamy Baird MBE, CEO of The BARBARA Alliance
We are at a turning point in dementia research. New diagnostics and treatments mean we can understand dementia earlier and identify people who could benefit from new approaches to care.
We are at a turning point in dementia research. New diagnostics and treatments mean we can understand dementia earlier and identify people who could benefit from new approaches to care.
But science alone will not deliver the breakthroughs patients and families urgently need. One of the biggest barriers is connecting the research data, people and research capabilities needed to turn promising discoveries into treatments.
That is why The BARBARA Alliance and the Health Data Research Service are partnering to speed up access to tackle one of the biggest barriers to dementia research: recruiting enough people into clinical studies to test promising new treatments.
Last week, the Prime Minister announced £33 million of Government funding through the Dame Barbara Windsor Dementia Goals programme, alongside additional funding from Bristol Myers Squibb, GSK and Gates Ventures. This £48 million industry partnership will be supported by HDRS, which has named dementia one as of the first priorities, because HDRS is well placed to help the partnership succeed by improving how approved researchers securely access health data held across the UK.
We have the ingredients for success. We need to connect them.
The UK has world-leading scientists, rich health data, pioneering diagnostic technology and clinical trial expertise. Yet these strengths are not well connected.
Clinical trials are how we find out whether new treatments work and are safe. Without enough people taking part, promising treatments cannot be tested, approved and made available. So far, the UK has played only a small part in late-stage dementia trials. Finding the right people is slow and costly, and research and health services have often worked separately.
For people living with dementia and their families, that means time and opportunity that cannot easily be recovered.
Two organisations, one shared goal
The BARBARA Alliance brings together government, industry, academia, charities, the NHS, regulators and people with lived experience. Its flagship programme, BARBARA, aims to connect the UK’s existing dementia research, clinical trial capabilities and new diagnostic tests through one coordinated approach. The aim is to make it easier to find suitable participants, help more people take part in trials and let researchers test promising treatments sooner. Taking part in research should not depend on where you live or how close you are to a specialist centre.
HDRS is improving how approved researchers securely access health data held across the UK, making it simpler, faster and more consistent. When health data from different sources is studied together, it reveals patterns and connections that would otherwise stay hidden. For dementia, that could help researchers understand how the disease develops, design better clinical trials and see how new treatments work in everyday care. Only approved researchers can access data, and only for approved research, with clear safeguards in place.
BARBARA is working to remove the barriers between people and research. HDRS is working to remove the barriers between researchers and the data they need.
It works both ways. BARBARA understands the practical challenges faced by researchers, clinicians and patients, and that insight can help shape HDRS around real needs.
Building public trust into progress
Success is not measured by how much data we can access, but about whether we make a difference to people’s lives. Nearly one million people are living with the condition in the UK today, and around one in two people will be affected by dementia in their lifetime, either living with the condition, being a carer or both. For them, faster research means earlier answers, more chances to take part in trials and greater hope of effective treatments.
Using health data comes with a responsibility to protect it. Through BARBARA’s People’s Forum and HDRS’s commitment to public involvement, people affected by dementia can help shape what research is prioritised and how the systems behind it are governed.
A blueprint for a more connected research system
Success will mean more people taking part in research, more representative trials and promising discoveries reaching patients sooner. It could also show a way of working that benefits other conditions.
The next breakthrough in dementia may begin in a laboratory. Whether it reaches patients will depend on how well we connect the people, data and systems needed to make it happen.
That is the opportunity in front of us, and the shared ambition we are determined to deliver.
Partnering for impact: why HDRS and The BARBARA Alliance are joining forces to accelerate dementia research
By Dr Melanie Ivarsson, CEO of Health Data Research Service (HDRS), and Jessamy Baird MBE, CEO of The BARBARA Alliance
CEO Update
October saw an important milestone for HDRS, with dementia announced as one of our first priorities, a new round of…
Building HDRS through learning
How driver projects across the UK are shaping our national health data infrastructure